Efficacy of ibritumomab tiuxetan (Zevalin) following remission induction therapy for relapse of follicular lymphoma

Efficacy of ibritumomab tiuxetan (Zevalin) following remission induction therapy for relapse of follicular lymphoma - Ibritumomab tiuxetan (Zevalin) for relapse of follicular lymphoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007950

Enrollment

Registered

2012-05-15

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Follicular lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with relapsed follicular lymphoma of clinical stage 3 or 4. 2) Lymphoma cells were CD20-positive by immunohistochemistry or flow cytometry. 3) Induction treatment for relapsed follicular lymphoma has been completed, within 3 months of registration. 4) Partial or complete remission has been achieved by induction therapy for relapsed follicular lymphoma. 5) Performance status (ECOG) were either 0 or 1. 6) Written informed consent was obtained.

Exclusion criteria

Exclusion criteria: 1) Patients with uncontrollable infection. 2) Intolerable allergy for rituximab or drugs derived from murine proteins. 3) Previous history of allogeneic stem cell transplant. 4) Pregnant (or possibly pregnant) patient 5) Patients receiving anti-coagulants or anti-thrombotic agents. 6) Patients with hemorrhagic symptoms. 7) Patients receiving external radiation for more than 25% of total bone marrow. 8) Patients planning to undergo rituximab maintenance therapy.

Design outcomes

Primary

Measure	Time frame
2-year progression-free survival rate	—

Secondary

Measure	Time frame
Progression-free survival Overall survival Complete remission rate	—

Countries

Japan

Contacts

Public ContactFumihiko Nakamura

The University of Tokyo Hospital Department of Hematology and Oncology

fnakamur-tky@umin.ac.jp+81-3-5800-8741

Outcome results